



Cite this: *RSC Adv.*, 2022, 12, 26704

Development and validation of the UPLC-MS method for simultaneous determination of six new psychoactive substances

Zhouhong Tan,^{ab} Yunbo Wen,^b Kai Yang,^c Xia Zhao,^a Xiaoli Yang^{*a} and Jieli He ^{*ab}

The combined abuse of benzodiazepines and antipsychotics has become a global problem, and to develop a highly sensitive and selective method for monitoring of benzodiazepine hypnotics and antipsychotics is urgently necessary. In this work, we established a rapid method for the simultaneous determination of benzodiazepines (diazepam, alprazolam, triazolam, and estazolam) and antipsychotic drugs (clozapine, and chlorpromazine) based on ultra performance liquid chromatography-mass spectrometry (UPLC-MS). The accuracy, precision, limit of detection (LOD), limit of quantification (LOQ), specificity, matrix effect and carry-over effect were verified in detail. The results of the recovery and repeat experiments proved that the proposed UPLC-MS method possessed very satisfactory accuracy and precision. The LOD and LOQ of the six psychoactive substances were as low as 0.001–0.005 and 0.005–0.01 $\mu\text{g L}^{-1}$, respectively. The proposed method was employed to analyze urine samples which were pretreated with a protein precipitation process. The potential influences of precipitants on the analysis results were evaluated statistically, and 0.1% formic acid/acetonitrile/water was selected as the optimum precipitation agent. The detection of the targets was free from matrix and carryover effects.

Received 5th August 2022
Accepted 9th September 2022

DOI: 10.1039/d2ra04869h

rsc.li/rsc-advances

1. Introduction

New psychoactive substances (NPS) as structural variants of typical illicit drugs have become the most ideal substitutes for traditional drugs. Their synthesis is based on the structural parent nuclei of illegal substances, which are slightly modified to produce effects similar to those of known illegal substances (such as cannabinoids).¹ Due to subtle structural differences, most NPS were not detected by drug-detection systems, allowing criminals to evade the law.^{2–5} In recent years, with the continuous development of the internet network, the market of NPS has been expanding, and the abuse of NPS has become a global problem.^{6–8} In 2018, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) reported that one new NPS appears per week on average.^{9,10} By January 2021, more than 1000 NPS had been reported.³ In response to the growing number of NPS, the EMCDDA has implemented the EU Early Warning System (EWS), which aims to monitor, analyse and report on the growth trend of NPS.¹¹ From 2014 to 2019, the number of first identified NPS decreased from 100 to 53, and the prevalence of NPS also declined.^{11,12} However, seizures of NPS

are very limited, and the main categories of NPS seized are synthetic stimulants such as phenylethylamine and cathinone. In addition, there are currently no guidelines regarding the threshold reference standard value of NPS in biological samples, resulting in the difficulty of monitoring.¹³ Moreover, because of the quick regeneration of NPS, it was probably withdrawn from the sale market before they were uncovered, resulting in possible delays in validation and notification of NPS by the EWS.^{1,14}

With increasing control of NPS, clinical psychotropic prescription drugs have become the most popular NPS substances for criminals, such as diazepam, alprazolam and barbiturates. Prescription drugs are not only easier to obtain, but also can completely avoiding drug detection system. Among them, benzodiazepine hypnotics and antipsychotics are currently the two most popular of NPS substances sold on the black market. And both of them are central nervous system depressants. Benzodiazepines are GABA-A receptors that act on the limbic system and are mainly used to treat diseases such as anxiolytics, epilepsy, insomnia, convulsions and muscle relaxation.^{15–17} Antipsychotic drugs (such as chlorpromazine) mainly play a role in inhibiting the central nervous system by inhibiting the transmission of dopamine for the treatment of patients with schizophrenia and agitation.^{18,19} In addition to their therapeutic effects, these two types of drugs have serious side effects, such as slurred speech, unresponsiveness, delirium, coma, cognitive impairment, etc., especially after overdose in normal people. Long-term use will lead to serious drug tolerance, addiction,

^aCollege of Pharmacy, Dali University, Dali 671000, Yunnan, P. R. China. E-mail: hejieli@dali.edu.cn

^bYunnan Provincial Key Laboratory of Forensic Science, Kunming, 650223, Yunnan, P. R. China

^cPublic Security Bureau, Dali Bai Autonomous Prefecture, Dali 671000, Yunnan, P. R. China


withdrawal symptoms, extrapyramidal system and other risks.^{20–22} In addition, it is more serious that it will produce superimposed effect, leading to acute symptoms such as liver lung injury and even death if the two drugs are taken at the same time.^{23–25} As a result, two types of drugs are also often associated with various types of crime for different purposes, such as sexual assault, murder, robbery, assault, *etc.*, posing unprecedented challenges to public health and law enforcement everywhere.^{17,23} Therefore, it is particularly important to be able to quantitatively monitor the content of benzodiazepines and antipsychotics in body fluids.

At present, the commonly used detection methods for NPS substances include immunoassay, colorimetry, Raman spectroscopy, electrochemical method, liquid chromatography (HPLC), *etc.* However, these methods have low sensitivity and are not suitable for the detection of low content substances in human body, which may lead to false positive cases.^{26–28} Rapid qualitative and quantitative detection of NPS substances in conventional biological matrix samples (such as hair, urine, blood, nails) with high selectivity and sensitivity has become one of the most important research topic. Such as, Elmansi²⁹ used micellar electrokinetic chromatography (MEKC) for simultaneous detection of three types of benzodiazepines with the low detection limit of 0.7–1.5 $\mu\text{g mL}^{-1}$. However, this technique has the disadvantages of complex and time-consuming, which is not suitable for routine drug screening in clinical and forensic toxicology. Choudhary²³ developed a high performance thin layer chromatography mass spectrometry (HPTLC-MS) method with the advantage of low operating cost to detect benzodiazepines. Nevertheless, it is not able to detect multiple substances simultaneously. Jinlei³⁰ established a method based on gas chromatography-mass spectrometry (GC-MS) for the analysis of benzodiazepines in urine with the lower limit of quantification of 0.20–5.0 $\mu\text{g L}^{-1}$. But the sample treatment is time-consuming and requires derivatization. In comparison, the ultra-high liquid chromatography-tandem mass spectrometry (UPLC-MS) has better adaptability especially in the determination of multiple objects because of its high selectivity and sensitivity under multiple response monitoring model (MRM) and attracts much attention.³¹

Accurate qualitative and quantitative detection of NPS in biological samples is highly necessary. Compare with blood, urine sample can be obtained easily and collected noninvasively and rapidly, and also is easy to handle and operate. Moreover, blood sample usually clots quickly at room temperature, while urine is relatively stable. Therefore, urine is the most commonly used biological material, and it is essential to pretreat it before analysis. The currently common pretreatments are solid phase extraction (SPE), liquid liquid extraction (LLE) and protein precipitation (PP).^{32–35} SPE bases on the difference in partition coefficient between the solid phase and the liquid phase of the target to separate the target from urine sample. And it requires long-time extraction and complex multi-step process. LLE achieves the purpose of separation according to the different solubility of the target component in the solvent. Although it is not as complicated as SPE, a large amount of harmful volatile organic solvents is needed. PP is a method of precipitation by

using organic solvents (such as methanol, ethanol, acetone, *etc.*) that are miscible with water to significantly reduce the solubility of protein in water. By comparison, PP has several advantages of convenient, efficient and easy to automate, and becomes the most suitable method for urine pretreatment.

Herein, we developed a rapid and simple liquid chromatography-mass spectrometry technique to analyze benzodiazepines (diazepam, alprazolam, triazolam, estazolam) and antipsychotics (clozapine and chlorpromazine) simultaneously in urine sample after PP pretreatment, and provided a basis method for the quality control of NPS in clinical monitoring.

2. Experimental section

2.1 Chemicals and reagents

Diazepam (98.0%), chlorpromazine (99.0%), clozapine (99.0%), alprazolam (98.0%), triazolam (98.0%), and estazolam (99.0%) were provided by Dali State Public Security Bureau (Dali, China). Methanol was purchased from Honeywell International Company (Charlotte, USA). Formic acid was obtained from Thermo Fisher Scientific (Massachusetts, USA). Acetonitrile was provided by Shanghai Aladdin Industrial Co., Ltd. All reagents were of chromatographic grade. Ultrapure water was purified by a pure water system (DZG-303A, Tangle Corning Technology Factory, China) for prepared needed solutions. Filtration membrane (nylon66) with a diameter of 13 mm and 0.22 μm was purchased from Tianjin Jinrong Experimental Equipment Company (Tianjin, China).

The stock solutions of triazolam, estazolam, alprazolam, diazepam, and clozapine were separately prepared with a concentration of 10 $\mu\text{g mL}^{-1}$. A series of mixed standard working solutions with concentrations of 0.01, 0.025, 0.1, 0.5, 1.0, 2.0, 4.0, 10.0 $\mu\text{g L}^{-1}$ were prepared for calibration, verification and analysis. Methanol was used as diluent in the preparation of the individual stock solutions. All as-prepared solutions were stored at a 4 °C.

2.2 UPLC-MS conditions

Ultimate 3000 HPLC system coupled with a triple quadrupole mass spectrometer (Ultimate 3000-TSQ Quantis) with an electrospray ionization source (ESI) was employed and a hypersil gold column (1.9 mm particle size, 100 mm \times 2.1 mm i.d.) was thermostated at 30 °C. The mobile phase was composed of 0.05% formic acid in water (v/v, component A) and acetonitrile (component B), and the flow rate was 0.3 mL min^{-1} . The optimized gradient elution program of solvent B was as follows: 0–0.5 min, 10%; 0.5–0.7 min, 10–26.5%; 0.7–2.0 min, 26.5–70%; 2–3.2 min, 70%; 3.2–3.5 min, 70–90%; 3.5–7 min, 90%; 7–7.5 min, 90–26.5%; 7.5–12 min, 26.5–10%. In MRM mode, the analyte standard with a concentration of 1 $\mu\text{g mL}^{-1}$ (injection rate of 15 $\mu\text{L min}^{-1}$) was injected into the mass spectrum, and the parent ion peak of the substance was decided by optimizing the ion source spray voltage to ensure that the response intensity was above 10^6 . Collision energy, sheath gas and auxiliary gas flow rate were automatically optimized by the system. Under






Fig. 1 UPLC-MS chromatogram of analysed compounds.

optimized conditions, two ions with highest intensity were selected as characteristic peak ions, one for quantification and another for qualification. ESI was performed on positive ionization multi reaction monitoring (MRM) mode. ESI monitoring parameters were optimized as follows: ion source spray voltage, 3500 V; sheath gas flow rate, 25 L min⁻¹; auxiliary gas flow rate, 5 L min⁻¹; ion transfer tube temperature, 350 °C; atomization temperature, 300 °C. The retention time (RT) and ion parameters of the compounds studied in MRM mode are shown in Table 1, and the UPLC-MS spectra of the compounds analyzed under optimized conditions are shown in Fig. 1.

2.3 Methods validation

The established method was validated in accordance with the forensic toxicological methods validation protocols developed by the scientific working group on forensic toxicology (SWGTOX) and the European Medicines Agency (EMA).^{36,37} Validation contents include linearity, accuracy, precision, limit of detection (LOD), limit of quantification (LOQ), specificity, matrix effect, and carryover effect.

Calibration curves were obtained by analyzing mixture of standard solutions (containing diazepam, chlorpromazine, clozapine, alprazolam, triazolam, and estazolam) at eight concentration levels (0.01, 0.025, 0.1, 0.5, 1.0, 2.0, 4.0, 10.0 µg L⁻¹), and constructed by plotting the peak areas *versus* the

concentrations of analyte with linear regression. Linearity was considered satisfactory if the R^2 value was higher than 0.99. The standard serial solutions with three concentration gradients (0.1, 1.0 and 10.0 µg L⁻¹) were prepared to examine the accuracy and repeatability. Accuracy was evaluated by a blank spiked recovery experiment in methanol (HPLC grade) and calculated as (measured value/expected value) × 100%. Accuracy was assumed satisfactory if recoveries were in the range of 80–120%. For within-run precision estimation, six replicates at three concentrations of 0.1, 1.0 and 10.0 µg L⁻¹ were analyzed on a single day. One replicate was analyzed on 7 days for between-day precision investigation. The relative standard deviation (RSD) must less than 15%. The ratio of analyte response/signal and background noise (S/N) ≥ 3 is considered as LOD, and S/N ≥ 10 is LOQ. Specificity of the method was assessed by analyzing blank urine samples from six different sources after adding mixing standard solution of 0.1 µg L⁻¹. Carryover effect was evaluated by the influence of residue of high concentration sample on analysis results of blank negative sample, and the experiment was repeated for three times. Matrix effect evaluation was carried out by relative response of the standard solution and matrix sample spiked with the same concentration of analyte.

2.4 Urine sample pretreatment

Urine sample was pretreated by PP method. Total six blanks urine samples from healthy volunteers were collected and mixed. Add 35 mL of precipitant into 5 mL of the mixed urine sample, and then process for 10 min with ultrasound. After that, the urine sample was centrifuged for 10 min (10 000 r/min), and the supernatant was filtered by 0.22 µm membrane to obtain blank urine. The spike procedure was performed by adding some amounts of 0.5, 5.0 and 50.0 µg L⁻¹ of mixed standard working solution into the blank urine samples, and the obtained standard addition concentrations were 0.1, 1.0, and 10.0 µg L⁻¹ (in sextuplicate).

3. Results and discussion

3.1 Methods validation

Fig. 2 shows the calibration curves of the six standard solutions at concentration of 0.01, 0.025, 0.1, 0.5, 1.0, 2.0, 4.0, 10.0 µg L⁻¹ measured by UPLC-MS, and their correspondingly correlation regression equations are displayed in Table 2. The coefficients

Table 1 Retention times and parameters of MRM mode for the studied compounds

Analyte	Precursor ion	Quantification		Qualitication		RT (min)
		Production	CE (V)	Product ion	CE (V)	
Diazepam	285.1	154.1	26.95	193.1	31.33	6.15
Chlorpromazine	319.1	214.0	20.25	86.1	40.13	5.57
Clozapine	327.0	192.1	41.27	270.1	25.13	5.08
Triazolam	343.1	315.2	24.59	308.2	23.24	5.82
Alprazolam	308.9	204.6	40.55	281.0	25.72	5.85
Estazolam	295.2	241.1	21.51	267.0	24.08	5.68






Fig. 2 Calibration curves of six standard solutions measured by UPLC-MS.

of six analytes are all greater than 0.9990 in the range of 0.01–10.0 $\mu\text{g L}^{-1}$, indicating that the correction curves fit well and have good correlation within the linear range. The corresponding LOD and LOQ values of the six analytes (Table 2) are in the range of 0.001–0.005 and 0.01–0.005 $\mu\text{g L}^{-1}$, which are lower than that of most literature methods.^{38–41}

The intraday accuracy and precision of the proposed UPLC-MS method are expressed as the recovery rate and RSD correspondingly of the six analytes at three fortification levels assay (0.1, 1.0, 10.0 $\mu\text{g L}^{-1}$). As shown in Table 3, the average

recoveries of all six analytes ranged between 89.3–119.9%, 93.1–98.6% and 98.3–103.6% at the concentration of 0.1, 1.0 and 10.0 $\mu\text{g L}^{-1}$, respectively. The RSD values were 5.59–11.83%, 3.30–5.28% and 1.44–4.54% at 0.1, 1.0 and 10.0 $\mu\text{g L}^{-1}$, accordingly. Table 4 displays the between-day accuracy and precision. The average recoveries were between 89.5% and 108.9%, and the RSD values were < 15% for all analytes. The above results indicating the accuracy and precision of the offered method are satisfactory, especially at high concentration level.

3.2 Evaluation of precipitants for urine sample pretreatment

Protein precipitation method was used to pretreat the urine sample. The removal efficiency of urine protein changed with the different precipitant, which probably interfered with determination results of targets. Here, acetonitrile, methanol and acetonitrile water with 0.1% formic acid (V : V = 10 : 90) were adopted to pretreat the urine samples. Certain amounts of mixed standard solutions with the theoretical spiked concentration of 1.0 $\mu\text{g L}^{-1}$ were added into the obtained blank urine samples, and three parallel spiked recovery results were shown in Table 5. To check the outliers, the Grubbs test was employed and a 95% confidence level was selected. The G value was calculated by eqn (1), where x_q , \bar{x} and S are suspicious value, average value and standard deviations, respectively. The critical value of G is $G_{0.05,3} = 1.155$ (ref. 42).

$$G = \frac{|x_q - \bar{x}|}{S} \quad (1)$$

When acetonitrile was used as the precipitant, the questionable values of diazepam, chlorpromazine, clozapine, triazolam, alprazolam, and estazolam were 0.5865, 0.7754, 0.6538, 0.9757, 0.7252, and 0.7757, and corresponding G values were

Table 2 Regression equations, LOD and LOQ of six analytes

Analyte	Calibration curve	R^2	Range ($\mu\text{g L}^{-1}$)	LOD ($\mu\text{g L}^{-1}$)	LOQ ($\mu\text{g L}^{-1}$)
Diazepam	$Y = 6356.35X + 2.25$	0.9991	0.01–10.0	0.002	0.005
Chlorpromazine	$Y = 6471.17X - 25.67$	0.9992	0.01–10.0	0.001	0.005
Clozapine	$Y = 7830.00X + 5.51$	0.9990	0.01–10.0	0.001	0.005
Triazolam	$Y = 5828.78X + 31.11$	0.9992	0.01–10.0	0.002	0.005
Alprazolam	$Y = 3632.50X + 2.93$	0.9991	0.01–10.0	0.005	0.01
Estazolam	$Y = 4027.09X + 5.25$	0.9999	0.01–10.0	0.005	0.01

Table 3 Within-day accuracy and precision (in sextuplicate)

Analyte	0.1 $\mu\text{g L}^{-1}$		1.0 $\mu\text{g L}^{-1}$		10.0 $\mu\text{g L}^{-1}$	
	Average recovery (%)	RSD (%)	Average recovery (%)	RSD (%)	Average recovery (%)	RSD (%)
Diazepam	114.6	11.83	96.6	4.13	103.6	3.13
Chlorpromazine	111.6	10.04	93.1	5.28	101.8	1.44
Clozapine	113.5	6.14	98.6	3.43	98.5	2.71
Triazolam	119.9	6.64	97.8	3.30	100.7	4.54
Alprazolam	114.0	5.59	96.8	3.57	100.1	2.67
Estazolam	89.3	11.96	98.3	3.63	98.3	4.14



Table 4 Between-day accuracy and precision (in sextuplicate)

Analyte	0.1 µg L ⁻¹		1.0 µg L ⁻¹		10.0 µg L ⁻¹	
	Average recovery (%)	RSD (%)	Average recovery (%)	RSD (%)	Average recovery (%)	RSD (%)
Diazepam	103.8	10.40	90.4	7.28	93.7	10.63
Chlorpromazine	106.4	5.32	89.5	3.96	99.2	2.70
Clozapine	99.2	14.33	92.0	7.14	89.5	10.08
Triazolam	108.9	12.48	94.3	3.70	93.9	7.18
Alprazolam	99.2	4.76	92.2	5.05	93.1	7.54
Estazolam	94.8	5.81	96.6	1.72	97.4	0.95

Table 5 Statistic evaluation of Grubbs test

Extracting agent	Analyte	Measured values (µg L ⁻¹)			Mean values (µg L ⁻¹)	S
Acetonitrile	Diazepam	0.6815	0.6805	0.5865	0.6495	0.0546
	Chlorpromazine	0.7504	0.7380	0.7754	0.7546	0.0191
	Clozapine	0.6538	0.6056	0.5822	0.6139	0.0365
	Triazolam	0.9757	1.0285	1.0288	1.0110	0.0306
	Alprazolam	0.8055	0.7751	0.7252	0.7686	0.0405
	Estazolam	0.8216	0.7757	0.8529	0.8167	0.0388
Methylalcohol	Diazepam	0.7682	0.7534	0.7085	0.7434	0.0310
	Chlorpromazine	1.0066	1.0410	1.0185	1.0220	0.0175
	Clozapine	0.7550	0.7915	0.8210	0.7892	0.0331
	Triazolam	0.6932	0.7898	0.8028	0.7619	0.0599
	Alprazolam	0.6457	0.8945	0.7214	0.7539	0.1275
	Estazolam	0.8405	0.8199	0.7722	0.8109	0.0350
0.1% formic acid acetonitrile water	Diazepam	0.8734	0.8580	0.8917	0.8744	0.0169
	Chlorpromazine	1.0212	0.9868	0.9669	0.9916	0.0275
	Clozapine	0.8882	0.8519	0.8607	0.8669	0.0189
	Triazolam	1.0403	0.9919	0.9616	0.9980	0.0397
	Alprazolam	1.0036	0.9878	1.0052	0.9989	0.0010
	Estazolam	0.9381	0.9704	0.9900	0.9661	0.0262

1.1538, 1.0890, 1.0932, 1.1536, 1.0716, and 1.0567, which were all lower than $G_{0.05,3}$, indicating the x_q values should be retained. For methanol as the precipitant, the x_q values were 0.7085, 1.0410, 0.7550, 0.6932, 0.8945, 0.7722, and the calculated G values were 1.1258, 1.0857, 1.0332, 1.1469, 1.1027, and 1.1057, respectively. Therefore, all x_q values should not be discarded. Similarly, 0.8917, 1.0212, 0.8882, 1.0403, 0.9878, 0.9381 were x_q values when 0.1% formic acid acetonitrile water was as the precipitant. Correspondingly, the calculate G values of 1.0237, 1.0764, 1.1270, 1.0655, 1.1100, 1.0687 were also all lower than $G_{0.05,3}$, and all x_q values should be retained.

The significant difference in the analysis results of samples after different precipitant treatments were checked by F test. The 95% confidence level was selected in the statistical evaluation. The F value was calculated by eqn (2).

$$F = \frac{MS_1}{MS_2} \quad (2)$$

MS_1 and MS_2 represent the inter-group and the intra-group variance accordingly, where $MS_1 = \frac{SS_{\text{inter}}}{\nu_1}$, $MS_2 = \frac{SS_{\text{intra}}}{\nu_2}$, SS_{inter} and SS_{intra} are the sums of squares of deviations, and ν_1

and ν_2 are degree of freedom of inter and intra groups ($\nu_1 = k - 1$, $\nu_2 = N - k$, where k is the number of groups and N is the total number of samples). SS , MS_1 , MS_2 and F of the six analytes were shown in Table 6. Compare the calculated F value with the critical value $F_{0.05,(\nu_1, \nu_2)}$, and if $F > F_{0.05,(\nu_1, \nu_2)}$, it means that the results are significant different and the differences are statistically significant. Here, the critical value of $F_{0.05,(2,6)}$ was 6.060,

Table 6 Statistic evaluation of F test

Analyte	source of variation	SS	ν (df)	MS	F
Diazepam	Inter-group	0.077	2	0.038	27.152
	Intra-group	0.008	6	0.001	
Chlorpromazine	Inter-group	0.129	2	0.064	135.256
	Intra-group	0.003	6	0.000	
Clozapine	Inter-group	0.127	2	0.063	32.325
	Intra-group	0.012	6	0.002	
Triazolam	Inter-group	0.118	2	0.059	29.000
	Intra-group	0.012	6	0.002	
Alprazolam	Inter-group	0.113	2	0.057	9.440
	Intra-group	0.036	6	0.006	
Estazolam	Inter-group	0.046	2	0.023	20.366
	Intra-group	0.007	6	0.001	



Table 7 Statistic evaluation of q test^a

Analyte	Comparison group	$ \bar{x}_A - \bar{x}_B $	MS	q
Diazepam	1 and 2	0.094	0.001	5.15
	1 and 3	0.225	0.001	12.32
	2 and 3	0.131	0.001	7.18
Chlorpromazine	1 and 2	0.267	0.001	14.62
	1 and 3	0.237	0.001	12.98
	2 and 3	0.030	0.001	1.64
Clozapine	1 and 2	0.175	0.001	9.59
	1 and 3	0.253	0.001	13.86
	2 and 3	0.078	0.001	4.27
Triazolam	1 and 2	0.249	0.002	9.64
	1 and 3	0.013	0.002	0.50
	2 and 3	0.236	0.002	9.14
Alprazolam	1 and 2	0.015	0.006	0.34
	1 and 3	0.230	0.006	5.14
	2 and 3	0.245	0.006	5.48
Estazolam	1 and 2	0.006	0.001	0.33
	1 and 3	0.149	0.001	8.16
	2 and 3	0.155	0.001	8.49

^a 1 was acetonitrile group; 2 was methanol group; 3 was 0.1% formic acid acetonitrile water group.




Fig. 3 MRM chromatograms of spiked urine sample (1) and mixed standard working solution (2).

and the F values of the six analytes were all greater than $F_{0.05,(2,6)}$. Therefore, it was concluded that the recovery results of urine samples after different precipitants treatment are significant different and the differences are statistically significant.

After confirming the significant differences among the three precipitants, q test should be used for pairwise comparison of the recovery rates of each group for the investigation of the best

precipitants. The 95% confidence level was selected in the statistical evaluation. The q value was calculated by eqn (3).

$$q = \frac{|\bar{x}_A - \bar{x}_B|}{\sqrt{\frac{MS}{2} \left(\frac{1}{n_A} + \frac{1}{n_B} \right)}} \quad (3)$$

\bar{x}_A and \bar{x}_B is the respective average values of the two groups of data compared, n_A and n_B is corresponding detection times of the two groups of data.

As shown in Table 7, the differences between every two groups of acetonitrile group, methanol group and 0.1% formic acid acetonitrile water group were significant in both diazepam and clozapine analysis. For chlorpromazine and triazolam determination, there were no significant differences between methanol and 0.1% formic acid acetonitrile water group, acetonitrile and 0.1% formic acid acetonitrile water group, respectively. For both alprazolam and estazolam testing, there were not significantly different between acetonitrile and methanol group. Combined with the recovery results which displayed in Table 5, 0.1% formic acid and acetonitrile water was chosen as the best precipitant for urine pretreatment in the following study.

3.3 Validation of the proposed method to determine the urine sample

To validate the application of the proposed UPLC-MS method in real samples monitoring, it was employed to determine the spiked urine sample after pretreating by acetonitrile water with 0.1% formic acid ($V:V = 10:90$). Add appropriate amounts of standard mixed working solutions into the obtained blank urine samples to get 0.1, 1.0, 10.0 $\mu\text{g L}^{-1}$ spiked solutions, and then determine the all six analytes (in sextuplicate). The MRM chromatograms of mixed standard working solution and spiked urine sample are displayed in Fig. 3. As it shows, the impurity peaks of endogenous compounds in urine samples would not interfere with the target analytes. Compare with the standard working solution of the same concentration, the impurity peaks of endogenous compounds in urine samples would not interfere with the detection of the targets. The average recoveries and RSD values of the analytes were shown in Table 8. The recoveries of all target compounds were 81.2–104.1% with RSD of 2.44–12.01%. Together, these results suggested the proposed method for real urine sample determination is of high specificity, good precision and accuracy.

Table 8 Recovery experiments on spiked urine samples

Analyte	0.1 $\mu\text{g L}^{-1}$		1.0 $\mu\text{g L}^{-1}$		10.0 $\mu\text{g L}^{-1}$	
	Average recovery (%)	RSD (%)	Average recovery (%)	RSD (%)	Average recovery (%)	RSD (%)
Diazepam	87.0	7.57	87.3	3.99	97.0	4.99
Chlorpromazine	100.3	5.83	98.9	2.44	104.1	3.31
Clozapine	81.2	10.03	84.5	3.70	97.8	4.37
Triazolam	99.8	5.65	100.8	6.51	103.0	3.58
Alprazolam	83.1	12.01	96.4	4.09	101.0	3.39
Estazolam	81.6	6.74	97.1	5.67	96.7	4.84



Table 9 The evaluation of matrix effects

Analyte	0.1 $\mu\text{g L}^{-1}$		1.0 $\mu\text{g L}^{-1}$		10.0 $\mu\text{g L}^{-1}$	
	Average recovery (%)	RSD (%)	Average recovery (%)	RSD (%)	Average recovery (%)	RSD (%)
Diazepam	76.0	7.54	90.0	3.64	93.6	4.56
Chlorpromazine	89.1	6.07	106.3	2.23	102.2	3.02
Clozapine	71.7	9.94	85.8	3.37	99.3	3.99
Triazolam	79.4	5.60	103.0	5.94	102.2	3.27
Alprazolam	108.5	11.29	99.6	3.71	101.0	3.09
Estazolam	91.6	6.64	98.8	5.17	98.4	4.42

Matrix effect is always an annoying problem in UPLC-MS analysis. The exogenous and endogenous impurities including salts and other matrix components in urine samples would flow out from the column with the target compounds and enter into ionization source, which might seriously affect the ionization process of the target compounds and lead to the inhibition or enhancement of ionization signals. In ESI mode, chlorpromazine and triazolam produced ion-enhancing effects, while the other four analytes (diazepam, clozapine, alprazolam and estazolam) showed different degrees of ion inhibition. To verify the influence of matrix effects in urine, the relative responses of target analytes in spiked blank urine samples and standard solutions with the same concentrations were explored for 6 parallel measurements and the results are displayed in Table 9. If values of average recovery within $(100 \pm 25)\%$ and $\text{RSD} < 15\%$, the matrix effect bears almost no influence on the method. At the concentrations of 1.0 and 10.0 $\mu\text{g L}^{-1}$, the average recovery and RSD values of all six analytes were in the range of 85.8–106.3% and 2.23–5.94%, respectively. Even as low as 0.1 $\mu\text{g L}^{-1}$, the matrix effect also could be ignored in all but clozapine analysis.

Carryover effect was also studied in detail. After injecting of high concentration of 10.0 $\mu\text{g L}^{-1}$ spiked urine sample, the blank negative sample was analyzed immediately. The corresponding response signals of negative sample for three repeated experiments were all lower than the detection limit, implying the carryover effect was mostly negligible.

4. Conclusions

In this study, the UPLC-MS method with good specificity, accuracy and high precision was developed for qualitative and quantitative analysis of six new psychotropic substances (diazepam, chlorpromazine, clozapine, triazolam, alprazolam and estazolam). Under optimized chromatographic conditions and positive ionization mode of UPLC-MS technology, all substances show good linearity in the range of 0.01–10 $\mu\text{g L}^{-1}$. The detection and quantification limits can reach 0.001 and 0.005 $\mu\text{g L}^{-1}$, respectively. The matrix and carry-over had no effects on the results of detection, and could be ignored. Further more, the protein precipitation method was used to pretreat the urine samples, and effects of precipitants were analyzed statistically and evaluated. The 0.1% formic acid acetonitrile water was chosen as the optimal precipitant. In summary, the

established method is sensitive, specific, simple and rapid, which can be applied in clinical and forensic toxicological analysis.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by the Opening Foundation of Yunnan Provincial Key Laboratory of Forensic Science (No. 2020SKF02) and scholarship for Academic Leader of Yunnan Province (No.2018HB003).

Notes and references

- 1 E. Y. Chung, H. J. Cha, H. K. Min and J. Yun, *Arch. Pharmacol. Res.*, 2021, **44**, 402.
- 2 K. F. da Cunha, K. D. Oliveira, M. A. Huestis and J. L. Costa, *J. Anal. Toxicol.*, 2020, **44**, 697.
- 3 F. K. Nzekoue, M. Agostini, M. Verboni, C. Renzoni, L. Alfieri, S. Barocci, M. Ricciutelli, G. Caprioli and S. Lucarini, *J. Pharm. Biomed. Anal.*, 2021, **205**, 114310.
- 4 M. Pettersson Bergstrand, M. R. Meyer, O. Beck and A. Helander, *Drug Test. Anal.*, 2018, **10**, 496.
- 5 A. Y. Simão, M. Antunes, H. Marques, T. Rosado, S. Soares, J. Gonçalves, M. Barroso, M. Andraus and E. Gallardo, *Bioanalysis*, 2020, **12**, 1557.
- 6 L. Vardal, G. Wong, A. M. L. Oiestad, S. Pedersen-Bjergaard, A. Gjølstad and E. L. Oiestad, *Anal. Bioanal. Chem.*, 2018, **410**, 4967.
- 7 L. Garcia, N. B. Tiscione, D. T. Yeatman and L. Richards-Waugh, *J. Anal. Toxicol.*, 2021, **45**, 462.
- 8 S. Dunlop, K. Hayes, P. Leavy, D. Cusack and R. Maguire, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2017, **1064**, 22.
- 9 K. F. da Cunha, K. D. Oliveira, M. S. Cardoso, A. C. F. Arantes, P. H. P. Coser, L. N. Lima, A. C. S. Maluf, M. A. C. Comis, M. A. Huestis and J. L. Costa, *Drug Alcohol Depend.*, 2021, **227**, 108962.
- 10 L. Orsolini, S. Chiappini, J. M. Corkery, A. Guirguis, D. Papanti and F. Schifano, *Expert Rev. Neurother.*, 2019, **19**, 1253.



- 11 S. Castiglioni, N. Salgueiro-Gonzalez, L. Bijlsma, A. Celma, E. Gracia-Lor, M. S. Beldean-Galea, T. Mackulak, E. Emke, E. Heath, B. Kasprzyk-Hordern, A. Petkovic, F. Poretti, J. Rangelov, M. M. Santos, M. Sremacki, K. Styszko, F. Hernandez and E. Zuccato, *Water Res.*, 2021, **195**, 116983.
- 12 K. E. Grafinger, W. Bernhard and W. Weinmann, *Sci. Justice*, 2019, **59**, 459.
- 13 A. Peacock, R. Bruno, N. Gisev, L. Degenhardt, W. Hall, R. Sedefov, J. White, K. V. Thomas, M. Farrell and P. Griffiths, *Lancet*, 2019, **394**, 1668.
- 14 F. Pantano, S. Graziano, R. Pacifici, F. P. Busardò and S. Pichini, *Curr. Neuropharmacol.*, 2019, **17**, 818.
- 15 M. G. Kang and H. R. Lin, *J. Anal. Toxicol.*, 2019, **43**, 96–103.
- 16 H. Garcez, C. Fernandes, F. Barbosa, M. R. Pereira, C. Silveira, J. Marques-Teixeira and A. R. Goncalves, *Psychopharmacol.*, 2020, **237**, 1.
- 17 L. Banaszkiewicz, M. K. Wozniak, M. Kata, E. Domagalska, M. Wiergowski, B. Szpiech and A. Kot-Wasik, *J. Pharm. Biomed. Anal.*, 2020, **191**, 113569.
- 18 M. Choi, M. E. Barra, K. Newman and J. H. Sin, *J. Intensive Care Med.*, 2020, **35**, 1118.
- 19 Y. Cao, F. Zhao, J. Chen, T. Huang, J. Zeng, L. Wang, X. Sun, Y. Miao, S. Wang and C. Chen, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2020, **1147**, 122129.
- 20 T. Atkin, S. Comai and G. Gobbi, *Pharmacol. Rev.*, 2018, **70**, 197.
- 21 Z. L. Li, Z. Y. Zhang, T. W. Zhao, C. Y. Meng, Q. Y. Zhang and M. M. Wang, *Mikrochim. Acta*, 2020, **187**, 540.
- 22 H. Takeuchi, N. E. MacKenzie, D. Samaroo, O. Agid, G. Remington and S. Leucht, *Schizophr. Bull.*, 2020, **46**, 1439.
- 23 P. Choudhary, S. Bansal and K. L. Verma, *J. Planar Chromatogr. - Mod. TLC.*, 2020, **33**, 523.
- 24 S. Y. Cheng, W. Y. Chen, H. C. Liu, T. W. Yang, C. H. Pan, S. Y. Yang and C. J. Kuo, *Psychopharmacol.*, 2018, **235**, 3329.
- 25 K. Morgan, N. Martucci, A. Kozłowska, W. Gamal, F. Brzeszczynski, P. Treskes, K. Samuel, P. Hayes, L. Nelson, P. Bagnaninchi, J. Brzeszczynska and J. Plevris, *Biomed. Pharmacother.*, 2019, **111**, 1408.
- 26 S. M. Ahmad and J. M. F. Nogueira, *Talanta*, 2019, **199**, 195.
- 27 M. Pettersson Bergstrand, A. Helander, T. Hansson and O. Beck, *Drug Test. Anal.*, 2017, **9**, 640.
- 28 A. Shafi, A. J. Berry, H. Sumnall, D. M. Wood and D. K. Tracy, *Ther. Adv. Psychopharmacol.*, 2020, **10**, 2045125320967197.
- 29 H. Elmansi and F. Belal, *Microchem. J.*, 2019, **145**, 330.
- 30 L. Jinlei, A. Wurita, W. Xuejun, Y. Hongkun, G. Jie and C. Liqin, *Leg. Med.*, 2021, **48**, 101822.
- 31 S. Lehmann, T. Kieliba, J. Beike, M. Thevis and K. Mercer-Chalmers-Bender, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2017, **1064**, 124.
- 32 E. Lopez-Garcia, N. Mastroianni, C. Postigo, D. Barcelo and M. Lopez de Alda, *J. Chromatogr. A*, 2018, **1576**, 80.
- 33 C. de Paula, M. Jurisch, E. Piccin and R. Augusti, *Drug Test. Anal.*, 2018, **10**, 1348.
- 34 M. De Boeck, L. Moreels, W. Dehaen, J. Tytgat and E. Cuyper, *J. Pharm. Biomed. Anal.*, 2019, **164**, 57.
- 35 A. Furugen, A. Nishimura, M. Kobayashi, T. Umazume, K. Narumi and K. Iseki, *J. Pharm. Biomed. Anal.*, 2019, **168**, 83.
- 36 T. Scientific Working Group for Forensic, *J. Anal. Toxicol.*, 2013, **37**, 452.
- 37 S. M. R. Wille, W. Coucke, T. De Baere and F. T. Peters, *Curr. Pharm. Des.*, 2017, **23**, 5442.
- 38 M. Cobo-Golpe, A. de-Castro-Rios, A. Cruz, M. Paramo, M. Lopez-Rivadulla and E. Lendoiro, *Forensic Sci. Int.*, 2021, **326**, 110935.
- 39 A. Orfanidis, H. Gika, O. Mastroianni, A. Krokos, G. Theodoridis, E. Zaggelidou and N. Raikos, *Forensic Sci. Int.*, 2018, **290**, 137.
- 40 M. De Boeck, S. Missotten, W. Dehaen, J. Tytgat and E. Cuyper, *Forensic Sci. Int.*, 2017, **274**, 44.
- 41 X. Wang, Y. Zhuo, X. Tang, H. Qiang, W. Liu, H. Wu, P. Xiang, G. Duan and M. Shen, *Drug Test. Anal.*, 2020, **12**, 472.
- 42 F. Li, H. Zhao and Y. Chai, *Analytical Chemistry*, People's Medical Publishing House, Beijing, China, 2011.

